{
    "nctId": "NCT00888082",
    "briefTitle": "Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy",
    "officialTitle": "Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients Undergoing Adjuvant Chemotherapy: An Open Label, Randomised, Multi-Centre, Phase IIIb Study",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer, Ovarian Function",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 102,
    "primaryOutcomeMeasure": "The ovarian function will be considered as regained, if E2 measurements return to premenopausal levels (equal to or above 20 pg/ml), FSH measurements return to premenopausal levels (less than or equal to 40 IU/L)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathologically confirmed invasive breast carcinoma\n* Candidates for adjuvant chemotherapy for primary breast cancer\n* Premenopausal, verified before chemotherapy is begun as satisfying both cyclic vaginal bleeding and appropriate hormone levels\n\nExclusion Criteria:\n\n* Previous systemic chemotherapy\n* Pregnancy\n* Stage IV breast cancer",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}